| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
Revenue  | 10 | 34 | 88 | 76 | 296 | 338 | 399 | 429 | 333 | 379 | 295 | 430 |
| Expenses | 80 | 105 | 173 | 76 | 233 | 263 | 351 | 244 | 242 | 269 | 280 | 336 |
| EBITDA | -70 | -71 | -85 | -0 | 64 | 76 | 48 | 185 | 91 | 110 | 15 | 94 |
| Operating Profit % | -800 % | -210 % | -207 % | -4 % | 20 % | 21 % | 11 % | 43 % | 26 % | 28 % | 4 % | 21 % |
| Depreciation | 19 | 18 | 20 | 20 | 68 | 68 | 69 | 69 | 68 | 70 | 70 | 72 |
| Interest | 18 | 25 | 26 | 21 | 42 | 45 | 46 | 33 | 28 | 34 | 38 | 23 |
| Profit Before Tax | -107 | -114 | -130 | -40 | -47 | -38 | -67 | 83 | -4 | 6 | -93 | -0 |
| Tax | 0 | 0 | 0 | 0 | -41 | 5 | 2 | -16 | -4 | -5 | -4 | -5 |
| Net Profit | -107 | -114 | -130 | -40 | -6 | -42 | -69 | 99 | -0 | 11 | -89 | 5 |
| EPS in ₹ | 0.00 | -27.37 | -31.32 | -9.67 | -0.51 | -10.13 | -6.31 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 |
Onesource Specialty Pharma
Onesource Specialty Pharma
1,837.80
+13.20
(0.72%)
Market Cap
21,065.08 Cr
PE Ratio
-281.76
Volume
4,06,098.00
Day High - Low
1,884.00 - 1,791.00
52W High-Low
2,248.00 - 1,057.00
Key Fundamentals
Market Cap
21,065.08 Cr
EPS
-6.44
PE Ratio
-281.76
PB Ratio
3.57
Book Value
508.64
EBITDA
294.29
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
-0.29
Debt to Equity
0.21
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
OneSource Specialty Pharma receives in-principle approval from Karnataka government for Unit II expansion under KIP 2025-30, boosting global manufacturing capacity.
OneSource Specialty Pharma published audited Q4 & FY26 financial results ad in Financial Express and Lokmat on May 14, 2026 under SEBI Regulation 47, confirming regulatory compliance.
OneSource Drops Merger Plan in Current Form
May 14, 2026
May 14, 2026OneSource Specialty Pharma's board decides not to pursue the composite scheme of arrangement with SteriScience entities, citing plans to revisit after FY28 guidance delivery.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,796.50 | #1 4,31,040.53 | 37.54 | #1 58,220.10 | 6.38 | #1 11,565 | 25.80 | 45.78 | |
6,553.50 | 1,73,974.83 | 68.85 | 10,560.00 | 8.73 | 2,520 | 13.44 | 45.06 | |
4,350.40 | 1,47,237.30 | 69.56 | 13,753.00 | 19.18 | 2,028 | -26.91 | 48.80 | |
1,390.30 | 1,12,305.75 | 29.25 | 27,711.70 | -2.46 | 3,783 | -55.32 | 56.75 | |
1,091.20 | 1,09,800.25 | 21.16 | 26,719.70 | 13.65 | 5,242 | 7.82 | 74.27 | |
1,290.40 | 1,07,702.34 | 26.16 | 33,593.30 | -0.44 | 3,998 | -86.05 | 47.28 | |
2,262.90 | 1,03,424.31 | #1 19.40 | 27,487.50 | 19.98 | 5,345 | #1 87.72 | 44.88 | |
2,320.20 | 95,779.03 | 50.66 | 14,277.60 | 12.03 | 1,750 | 31.75 | 44.68 | |
1,433.70 | 83,269.53 | 23.73 | 33,384.70 | 3.21 | 3,376 | 1.99 | 47.10 | |
1,388.40 | 74,953.69 | 82.57 | 6,812.90 | #1 21.03 | 884 | 21.18 | 76.63 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-2.78 %
Net Income Growth
444.34 %
Cash Flow Change
36.71 %
ROE
-99.69 %
ROCE
-103.78 %
EBITDA Margin (Avg.)
-38.10 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 972 | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 | 8,210 |
| Fixed Assets | 354 | 633 | 1,231 | 1,361 | 863 | 6,118 | 2,719 |
| Current Assets | 25 | 99 | 511 | 228 | 176 | 1,086 | 1,426 |
| Capital Work in Progress | 543 | 431 | 490 | 335 | 188 | 218 | 314 |
| Investments | 0 | 0 | 0 | 5 | 20 | 16 | 439 |
| Other Assets | 75 | 195 | 722 | 309 | 238 | 1,199 | 0 |
| Total Equity & Liabilities | 972 | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 | 8,210 |
| Current Liabilities | 194 | 161 | 809 | 865 | 631 | 1,114 | 1,442 |
| Non Current Liabilities | 361 | 321 | 621 | 358 | 282 | 556 | 937 |
| Total Equity | 417 | 776 | 1,013 | 786 | 396 | 5,881 | 5,831 |
| Reserve & Surplus | 414 | 775 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Share Capital | 1 | 2 | 3 | 4 | 4 | 11 | 12 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 56 | 55 | -112 | 13 | 143 |
| Investing Activities | -207 | -692 | -68 | 511 | -201 |
| Operating Activities | -118 | -416 | -163 | -107 | -68 |
| Financing Activities | 381 | 1,162 | 118 | -391 | 412 |
Share Holding
| % Holding | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 37.77 % | 34.25 % | 29.79 % | 29.77 % | 29.93 % | 30.48 % |
| FIIs | 17.44 % | 18.54 % | 18.69 % | 19.39 % | 19.24 % | 17.50 % |
| DIIs | 12.56 % | 18.04 % | 18.10 % | 18.49 % | 18.81 % | 20.61 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.05 % | 12.50 % | 13.25 % | 12.42 % | 12.39 % | 12.18 % |
| Others | 19.18 % | 16.67 % | 20.17 % | 19.93 % | 19.63 % | 19.23 % |
| No of Share Holders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 Feb 2024 |  Change Of Name | NA | 14 Feb 2024 | 0.00 | 0.00 |
| 29 Jan 2025 |  Quarterly Result Announcement | NA | 29 Jan 2025 | 0.00 | 1,536.60 |
| 05 May 2025 | Quarterly Result Announcement | NA | 05 May 2025 | 1,591.50 | 1,593.00 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 1,995.90 | 1,855.40 |
| 22 Sept 2025 |  Annual General Meeting | NA | 22 Sept 2025 | 1,855.40 | 1,836.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 1,825.85 | 1,791.40 |
| 23 Jan 2026 | Quarterly Result Announcement | NA | 23 Jan 2026 | 1,754.10 | 1,537.70 |
| 13 May 2026 | Quarterly Result Announcement | NA | 13 May 2026 | 1,742.70 | 1,833.55 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 19, 2026
May 19, 2026General- UpdateMay 19, 2026
May 19, 2026General-UpdateMay 16, 2026
May 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2026
May 13, 2026Update On Composite Scheme Of AmalgamationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2026
May 13, 2026Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13 2026 For Approval Of The Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2026May 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2026
May 07, 2026Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 07, 2026
May 07, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 04, 2026
May 04, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2026
Apr 29, 2026General-UpdateApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 21, 2026
Apr 21, 2026Intimation Of "Renewal Of EU -GMP Certification For Onesource : Flagship Unit II FacilityApr 17, 2026
Apr 17, 2026Intimation Of ESG RatingApr 16, 2026
Apr 16, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 09, 2026
Apr 09, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Update On Composite Scheme Of ArrangementMar 06, 2026
Mar 06, 2026Announcement under Regulation 30 (LODR)-Credit RatingMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2026
Mar 04, 2026Intimation Regarding Receipt Of No Objection/ No Adverse Observation Letter From The National Stock Exchange Of India Limited / BSE Limited In Realation To The Draft Composite Scheme Of Arrangement And Amalgamation (Merger By Absorption).Feb 26, 2026
Feb 26, 2026Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2026
Feb 11, 2026Onesource Specialty Pharma Limited Has Informed The Exchange Regarding Disclosure Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares & Takeovers)Regulations 2011 And Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Feb 03, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Feb 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 30, 2026
Jan 30, 2026Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations 2011 And Regulation 7(2) Of SEBI (PIT) Regulations 2015Jan 28, 2026
Jan 28, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 28, 2026
Jan 28, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 25, 2026
Jan 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jan 24, 2026
Jan 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2026
Jan 24, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jan 24, 2026
Jan 24, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 23, 2026
Jan 23, 2026Board Meeting Outcome for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended December 31 2025Jan 23, 2026
Jan 23, 2026Allotment Of Equity Shares Under The Onesource Specialty Pharma Limited - Employee Stock Option Plan - 2021Jan 21, 2026
Jan 21, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 19, 2026
Jan 19, 2026Board Meeting Intimation for Intimation Of The Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 For Approval Of Unaudited Financial Results Of The Company For The Quarter Ended December 31 2Jan 19, 2026
Jan 19, 2026Corporate Action-Amalgamation/ Merger / DemergerJan 14, 2026
Jan 14, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 09, 2026
Jan 09, 2026Intimation Of The Press Release Of Credit Rating Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015Dec 31, 2025
Dec 31, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 59.35
ATR(14)
Volatile 78.08
STOCH(9,6)
Neutral 42.53
STOCH RSI(14)
Oversold 10.05
MACD(12,26)
Bearish -15.12
ADX(14)
Strong Trend 33.47
UO(9)
Bearish 47.84
ROC(12)
Downtrend And Accelerating -0.31
WillR(14)
Neutral -49.89
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
